Log in

Relevant bibliographies by topics / Triptoreline / Journal articles

To see the other types of publications on this topic, follow the link: Triptoreline.

Journal articles on the topic 'Triptoreline'

Author: Grafiati

Published: 4 June 2021

Last updated: 7 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Triptoreline.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Rossi, E., G. Esposito, F. Di Rella, A. Gravina, G. Landi, F. Nuzzo, C. Pacilio, K. Monaco, M. Piccirillo, and A. de Matteis. "Endocrine effects of letrozole + triptoreline compared to tamoxifen + triptoreline as adjuvant treatment of premenopausal patients with early breast cancer." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 578. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.578.

Full text

Abstract:

578 Background: Few data have been reported on endocrine effects of combining LHRH-analogues with aromatase inhibitors (AI) in premenopausal patients. However, promising data in postmenopausal patients make this information interesting in view of extending adjuvant AI to premenopausal patients. We are conducting a phase 3 trial (Hormonal adjuvant treatment bone effects (HOBOE)) comparing tamoxifen (Tam), letrozole (L) and L + zoledronate (Z) for the effect on bone mineral density at 1 year. Postmenopausal and premenopausal patients are eligible, the latter also receiving monthly triptorelin (Tr). Methods: This analysis is limited to 76 premenopausal patients with early endocrine-responsive breast cancer, 28 treated with Tam+Tr and 48 with L+Tr±Z, assuming that Z has no endocrine effects. Serum 17-β-estradiol, FSH, LH, Δ4-androstenedione, testosterone, dehydroepiandrosterone-solphate, progesterone, ACTH and cortisol are measured at baseline and after 6 months of treatment. We compared, for each hormone, 6-month values between treatment groups by applying Exact Wilcoxon-Mann-Whitney test. Results: Baseline values for all the hormones were comparable between treatment groups. At 6 months, statistically significant differences were found for estradiol, FSH, LH and cortisol (see table , with median and range values by treatment group). No differences were found in plasma levels of testosterone, progesterone, ACTH, androstenedione, and dehydroepiandrosterone between the two groups. Conclusions: These data support that letrozole compared to tamoxifen, in combination with triptorelin, induces a more intense estrogen suppression also in premenopausal patients. Such evidence makes reasonable the hypothesis that the higher efficacy of letrozole versus tamoxifen shown in postmenopausal patients could be confirmed also in premenopausal patients. [Table: see text] No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

2

Rossi, E., F. Perrone, G. Esposito, G. Landi, F. Di Rella, R. Thomas, C. Gallo, K. Monaco, A. Morabito, and A. de Matteis. "2050 POSTER Endocrine effects of adjuvant letrozole plus triptoreline versus tamoxifen plus triptoreline in premenopausal patients with early breast cancer." European Journal of Cancer Supplements 5, no. 4 (September 2007): 199. http://dx.doi.org/10.1016/s1359-6349(07)70812-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Siyanti, Nur. "Tinjauan Maqâshid al-Syarî’ah terhadap Hukuman Kebiri bagi Pelaku Tindak Pidana Pedophilia." Al-Jinayah: Jurnal Hukum Pidana Islam 3, no. 1 (March 22, 2018): 113–43. http://dx.doi.org/10.15642/aj.2017.3.1.113-143.

Full text

Abstract:

Abstract: Castration against felons involving in pedhofilia is proposed Indonesia. The proposal considered it as additional punishment. Castration can be done by getting rid of testicle or by injecting antiandrogen hormone such as cyproterone acetate (CPA), medroxyprogesterone acetate (MPA), leuprolide dan triptoreline which function to weaken testosterone hormone. Pedofilia is a sexually based crime targeting children by felons who suffer from abnormal sexual development. From the perspective of maqâshid al-syarî’ah, castration can be considered a part of protection of reason (hifzh al-‘aql). It should prevent perpetrator from doing such an evil deed and will protect community from this wrong doing. Keywords: Pedofilia, castration, maqâshid al-syarî’ah Abstrak: Hukuman kebiri bagi pelaku tindak pidana pedofilia merupakan tambahan hukuman berupa tindakan bedah dengan cara membuang testis sebagai penghasil hormon testosteron, atau dengan suntik kimia, yaitu dengan menyuntikkan hormon anti androgen seperti cyproterone acetate (CPA), medroxyprogesterone acetate (MPA), leuprolide dan triptoreline yang berfungsi untuk melemahkan hormon testosteron, yang diberikan kepada pelaku atas kejahatan yang dilakukan terhadap anak akibat kelainan perkembangan seksual pelaku yang abnormal. Maqâshid al-syarî’ah memandang bahwa tambahan hukuman kebiri, baik yang melalui metode bedah ataupun suntik kimia, bagi pelaku tindak pidana pedofilia adalah sebagai upaya dalam melindungi terpeliharanya akal (hifzh al-‘aql) dan relevan dengan tujuan hukum Islam, yaitu untuk melindungi masyarakat dari rasa takut akan ancaman kejahatan tersebut. Hukuman tersebut diharapkan mampu memberikan efek jera bagi pelaku, serta berfungsi preventif terhadap kemungkinan terjadinya pengulangan jenis kejahatan yang sama, dan represif dalam mendidik pelaku agar ia menjadi orang yang baik dan menyadari kesalahan. Kata Kunci: Maqâshid al-syarî’ah, hukuman kebiri, pedofilia.

APA, Harvard, Vancouver, ISO, and other styles

4

Quereda, F., J. Barroso, and P. Acién. "Individual and combined effects of triptoreline and gestrinone on experimental endometriosis in rats." European Journal of Obstetrics & Gynecology and Reproductive Biology 67, no. 1 (July 1996): 35–40. http://dx.doi.org/10.1016/0301-2115(96)02435-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Paule, B., N. Brion, and M. Truffinet. "Treatment of stage D2 prostate carcinoma with triptoreline (LH-RH agonist)/flutamide/cyclophosphamide. A pilot study." European Journal of Pharmacology 183, no. 5 (July 1990): 1701–2. http://dx.doi.org/10.1016/0014-2999(90)92000-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Saldana, Carolina, Laurent Salomon, Benoit Rousseau, Marie Chaubet-Houdu, Charlotte Joly, Guillaume Ploussard, Yves Allory, Christophe Tournigand, and Alexandre de la Taille. "Weekly paclitaxel versus ADT alone in localized high-risk prostate cancer: Results of a single-institution phase II trial." Journal of Clinical Oncology 33, no. 7_suppl (March 1, 2015): 37. http://dx.doi.org/10.1200/jco.2015.33.7_suppl.37.

Full text

Abstract:

37 Background: Adjuvant chemotherapy’s role after radical prostatectomy (RP) remains controversial in localized high-risk prostate cancer (HRPC). This phase II trial assessed the combination of weekly paclitaxel (WP) with androgen deprivation therapy (ADT) in this population. Methods: All eligible patients (pts) had undergone a laparoscopic RP with pelvic lymph node dissection for a localized HRPC defined with ≥1 of the following criteria: T3b-T4 post-operated Gleason score (GS) ≥8, PSA≥ 20 ng/mL, pN+, in Henri Mondor Hospital. Pts were randomly assigned to either triptoreline 11.25mg every 3 months during 3 years and 8 cycles of WP 100 mg/ m2 (WP arm, n=21) or triptoreline alone (ADT arm, n=26). The primary endpoint is disease free survival (DFS); events=PSA relapse, clinical and radiographic relapse, death. The planned number of pts was 152. Toxicity results indicated a good tolerability with neutropenic fever in 4.3% (n=1), and no negative impact on QoL in the WP arm (Ploussard, Prostate Cancer Prostatic Dis. 2010). Here we report 8-year DFS and overall survival (OS) results. Results: Between February 2005 and October 2007, 47 pts were enrolled. This trial was terminated prematurely because of slow accrual. After a mean follow-up of 8.4 y, we identified a PSA relapse in 25 pts (53%) and castrate-resistant prostate cancer occurred in 6 pts. No statistically difference was found in terms of either biochemical or clinical DFS (bDFS, cDFS) and OS: 8-year bDFS rate: 50% [n=11/22] in the WP arm vs 46% [n=12/26] in the ADT arm (p=0.79); 8-year cDFS rate: 95.4% [n=21/22] in the WP arm vs 88.5% [n=23/26] in the ADT arm (p=0.38). The 8-year OS rate is 90.9% (n=20/22) and 84.6% (n=22/26) respectively with no difference between treatment arms (p=0.51). No clinical, histological or biological variable demonstrated a difference in either 8-year bDFS, cDFS or OS rate. Conclusions: Provided that this trial is probably underpowered to detect a DFS benefit, adjuvant weekly paclitaxel after RP was not associated with any significant reduction in the risk of biological relapse or death compared to ADT alone in patients with localized HRPC. Chemotherapy should be only proposed in dedicated clinical trial for localized HRPC.

APA, Harvard, Vancouver, ISO, and other styles

7

Porcu, Eleonora, Luca Dal Prato, Renato Seracchioli, Raffaella Fabbri, Maria Longhi, and Carlo Flamigni. "Comparison between depot and standard release triptoreline in in vitro fertilization: pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results." Fertility and Sterility 62, no. 1 (July 1994): 126–32. http://dx.doi.org/10.1016/s0015-0282(16)56827-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Roussie, M., D. Royère, M. Guillonueau, J. Lansac, and J. P. Muh. "Human antral fluid IGF-I and oocyte maturity: effect of stimulation therapy." Acta Endocrinologica 121, no. 1 (July 1989): 90–94. http://dx.doi.org/10.1530/acta.0.1210090.

Full text

Abstract:

Abstract. Studies in animals have highlighted a possible role for growth factors, particularly IGF-I on cellular replication and cytodifferentiation in the ovary. At this time, few studies have been performed about IGF-I in the human ovary. From 38 women undergoing in Vitro Fertilization 293 antral fluids were collected and assessed for steroids (estradiol and progesterone), FSH and IGF-I. Two induction treatments were compared: clomiphene citrate/hMG (group A, N = 15), triptoreline/hMG (group B, N = 23). We also studied relationships between quantitative parameters and oocyte collection or oocyte corona cumulus complex maturity. In group B, the highest antral estradiol levels were found in follicles yielding an oocyte (p <0.05). Concerning antral progesterone, higher levels were observed in follicles collected from group A than in follicles collected from group B (p < 0.05); for this parameter, the highest levels were observed when an oocyte was harvested, whatever the treatment (p <0.05). Highest antral FSH levels were observed in group B (p <0.05). IGF-I levels were higher in follicles collected from group B than in follicles collected from group A (p <0.05) and antral IGF-I levels differed between mature and immature oocyte corona cumulus complex in group B (p <0.05). These results, which are in keeping with studies about biological action of IGF-I in animal or human follicles or granulosa cells, led us to hypothesize a role for IGF-I in human follicular recruitment and maturation, a role that possibly is enhanced during GnRH analogue and gonadotropin therapy.

APA, Harvard, Vancouver, ISO, and other styles

9

Grimaldi, C., H. Bleiberg, F. Gay, M. Messner, P. Rougier, T. C. Kok, L. Cirera, et al. "Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial." Journal of Clinical Oncology 16, no. 2 (February 1998): 411–17. http://dx.doi.org/10.1200/jco.1998.16.2.411.

Full text

Abstract:

PURPOSE The aim of the study was to evaluate the efficacy of antiandrogen therapy on overall survival and response in unresectable hepatocellular carcinoma (HCC). PATIENTS AND METHODS A total of 244 patients with unresectable HCC were included in this multicentric double-blind trial. According to a two-by-two factorial design, patients were randomly assigned to receive one of the following treatments: pure antiandrogen plus placebo (A+P group, 60 patients); luteinizing hormone-releasing hormone (LHRH) agonist plus placebo (LHRH+P group, 62 patients); pure antiandrogen plus LHRH agonist (A+LHRH group, 62 patients); or placebo plus placebo (P+P group, 60 patients). Pure antiandrogen consisted of Anandron (Roussel-Uclaf Laboratory, Romainville, France) administered orally (300 mg daily for 1 month, then 150 mg daily). LHRH consisted of goseriline acetate (3.6 mg) or triptoreline (3.75 mg) administered monthly by subcutaneous injection. Treatment was given until death. Response was evaluated every 8 weeks according to World Health Organization (WHO) criteria. RESULTS Six patients were considered ineligible. One patient had a complete response (A+P arm) and three had a partial response (two in the LHRH+P arm and one in the A+LHRH arm). An overall log-rank test did not demonstrate any significant difference in survival among the four arms. Taking the factorial design into account, comparison of survival showed no significant difference between Anandron-containing regimens and others, or between LHRH-containing regimens and others. No serious side effects occurred for any regimen. CONCLUSION This controlled study shows clearly the lack of efficacy of androgen treatment in unresectable HCC.

APA, Harvard, Vancouver, ISO, and other styles

10

Celio, L., A. Martinetti, L. Ferrari, R. Buzzoni, E. Bombardieri, N. Zilembo, L. Maiorino, and E. Bajetta. "The LHRH analogue triptoreline (TAP) with or without the aromatase inhibitor formestane (4-OHA) in premenopausal advanced breast cancer: A study by the I.T.M.O. group." European Journal of Cancer 33 (September 1997): S155. http://dx.doi.org/10.1016/s0959-8049(97)85286-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Heidenreich, Axel. "CLINICAL EFFICACY AND SAFETY OF TRIPTORELINE PAMOATE IN THE MANAGEMENT OF ADVANCED PROSTATE CANCER IN 1432 PATIENTS – RESULTS OF A PROSPECTIVE NON- INTERVENTIONAL SURVEILLANCE STUDY." Journal of Urology 179, no. 4S (April 2008): 180. http://dx.doi.org/10.1016/s0022-5347(08)60521-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Triptorelin see Cyproterone/triptorelin/buserelin." Reactions Weekly &NA;, no. 299 (May 1990): 11. http://dx.doi.org/10.2165/00128415-199002990-00051.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Forsback, Ari-Pekka, Panu Noppari, Jesse Viljanen, Jari Mikkola, Mika Jokinen, Lasse Leino, Simon Bjerregaard, Camilla Borglin, and Janet Halliday. "Sustained In-Vivo Release of Triptorelin Acetate from a Biodegradable Silica Depot: Comparison to Pamorelin® LA." Nanomaterials 11, no. 6 (June 16, 2021): 1578. http://dx.doi.org/10.3390/nano11061578.

Full text

Abstract:

Triptorelin acetate was encapsulated into silica microparticles by spray-drying a mixture of colloidal silica sol and triptorelin acetate solution. The resulting microparticles were then combined with another silica sol containing silica nanoparticles, which together formed an injectable silica-triptorelin acetate depot. The particle size and surface morphology of the silica-triptorelin acetate microparticles were characterized together with the in vitro release of triptorelin, injectability and rheology of the final injectable silica-triptorelin acetate depot. In vivo pharmacokinetics and pharmacodynamics of the silica-triptorelin acetate depot and Pamorelin® were evaluated and compared in Sprague-Dawley male rats after subcutaneous administration. Serum samples up to 91 days were collected and the plasma concentrations of triptorelin and testosterone were analyzed with ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS). In vivo pharmacokinetics showed that injections of the silica-triptorelin acetate depot gave 5-fold lower Cmax values than the corresponding Pamorelin® injections. The depot also showed a comparable sustained triptorelin release and equivalent pharmacodynamic effect as the Pamorelin® injections. Detectable triptorelin plasma concentrations were seen with the depot after the 91-day study period and testosterone plasma concentrations remained below the human castration limit for the same period.

APA, Harvard, Vancouver, ISO, and other styles

14

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1198 (April 2008): 43–44. http://dx.doi.org/10.2165/00128415-200811980-00134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1208 (June 2008): 29. http://dx.doi.org/10.2165/00128415-200812080-00093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 770 (September 1999): 10. http://dx.doi.org/10.2165/00128415-199907700-00032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1318 (September 2010): 43. http://dx.doi.org/10.2165/00128415-201013180-00152.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1318 (September 2010): 44. http://dx.doi.org/10.2165/00128415-201013180-00154.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1328 (November 2010): 42–43. http://dx.doi.org/10.2165/00128415-201013280-00150.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1311 (July 2010): 41. http://dx.doi.org/10.2165/00128415-201013110-00144.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 813 (August 2000): 12. http://dx.doi.org/10.2165/00128415-200008130-00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1058 (July 2005): 18. http://dx.doi.org/10.2165/00128415-200510580-00052.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 555 (June 1995): 12. http://dx.doi.org/10.2165/00128415-199505550-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 952 (May 2003): 15. http://dx.doi.org/10.2165/00128415-200309520-00059.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1241 (February 2009): 39–40. http://dx.doi.org/10.2165/00128415-200912410-00114.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1178 (November 2007): 34. http://dx.doi.org/10.2165/00128415-200711780-00098.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1188 (February 2008): 22. http://dx.doi.org/10.2165/00128415-200811880-00072.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1148 (April 2007): 33. http://dx.doi.org/10.2165/00128415-200711480-00107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1398 (April 2012): 41. http://dx.doi.org/10.2165/00128415-201213980-00151.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1431 (December 2012): 37. http://dx.doi.org/10.2165/00128415-201214310-00128.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

&NA;. "Triptorelin." Reactions Weekly &NA;, no. 1386 (January 2012): 35. http://dx.doi.org/10.2165/00128415-201213860-00126.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Bellet, Meritxell, Kathryn P. Gray, Prudence A. Francis, István Láng, Eva Ciruelos, Ana Lluch, Miguel Angel Climent, et al. "Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy." Journal of Clinical Oncology 34, no. 14 (May 10, 2016): 1584–93. http://dx.doi.org/10.1200/jco.2015.61.2259.

Full text

Abstract:

Purpose To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus triptorelin. Patients and Methods Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached. Blood sampling time points were 0, 3, 6, 12, 18, 24, 36, and 48 months. Serum estrogens were measured with a highly sensitive and specific assay. This preplanned 12-month analysis evaluated E2, E1, E1S, follicle-stimulating hormone, and luteinizing hormone levels in all patients and the proportion of patients with E2 levels greater than 2.72 pg/mL at any time point during treatment with exemestane plus triptorelin. Results One hundred sixteen patients (exemestane, n = 86; tamoxifen, n = 30; median age, 44 years; median E2, 51 pg/mL; 55% prior chemotherapy) started triptorelin and had one or more samples drawn. With exemestane plus triptorelin, median reductions from baseline E2, E1, and E1S levels were consistently ≥ 95%, resulting in significantly lower levels than with tamoxifen plus triptorelin at all time points. Among patients on exemestane plus triptorelin, 25%, 24%, and 17% had an E2 level greater than 2.72 pg/mL at 3, 6, and 12 months, respectively. Baseline factors related to on-treatment E2 level greater than 2.72 pg/mL were no prior chemotherapy (P = .06), higher body mass index (P = .05), and lower follicle-stimulating hormone and luteinizing hormone (each P < .01). Conclusion During the first year, most patients on exemestane plus triptorelin had E2 levels below the defined threshold of 2.72 pg/mL, consistent with levels reported in postmenopausal patients on aromatase inhibitors, but at each time point, at least 17% of patients had levels greater than the threshold.

APA, Harvard, Vancouver, ISO, and other styles

33

Rossi, Emanuela, Alessandro Morabito, Ermelinda De Maio, Francesca Di Rella, Giuseppe Esposito, Adriano Gravina, Vincenzo Labonia, et al. "Endocrine Effects of Adjuvant Letrozole + Triptorelin Compared With Tamoxifen + Triptorelin in Premenopausal Patients With Early Breast Cancer." Journal of Clinical Oncology 26, no. 2 (January 10, 2008): 264–70. http://dx.doi.org/10.1200/jco.2007.13.5319.

Full text

Abstract:

PurposeTo compare the endocrine effects of 6 months of adjuvant treatment with letrozole + triptorelin or tamoxifen + triptorelin in premenopausal patients with early breast cancer within an ongoing phase 3 trial (Hormonal Adjuvant Treatment Bone Effects study).Patients and MethodsProspectively collected hormonal data were available for 81 premenopausal women, of whom 30 were assigned to receive tamoxifen + triptorelin and 51 were assigned letrozole + triptorelin ± zoledronate. Serum 17-β-estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), Δ4-androstenedione, testosterone, dehydroepiandrosterone-sulfate, progesterone, adrenocorticotropic hormone (ACTH), and cortisol were measured at baseline and after 6 months of treatment. For each hormone, 6-month values were compared between treatment groups by the Wilcoxon-Mann-Whitney exact test.ResultsMedian age was 44 years for both groups of patients. Letrozole + triptorelin (± zoledronate) induced a stronger suppression of median E2 serum levels (P = .0008), LH levels (P = .0005), and cortisol serum levels (P < .0001) compared with tamoxifen + triptorelin. Median FSH serum levels were suppressed in both groups, but such suppression was lower among patients receiving letrozole, who showed significantly higher median FSH serum levels (P < .0001). No significant differences were observed for testosterone, progesterone, ACTH, androstenedione, and dehydroepiandrosterone between the two groups of patients.ConclusionLetrozole in combination with triptorelin induces a more intense estrogen suppression than tamoxifen + triptorelin in premenopausal patients with early breast cancer.

APA, Harvard, Vancouver, ISO, and other styles

34

Yousefvand, Milad, Zahra Mohammadi, Farzaneh Ghorbani, Rasoul Irajirad, Hormoz Abedi, Somayyeh Seyedi, Arash Papi, and Alireza Montazerabadi. "Investigation of Specific Targeting of Triptorelin-Conjugated Dextran-Coated Magnetite Nanoparticles as a Targeted Probe in GnRH+ Cancer Cells in MRI." Contrast Media & Molecular Imaging 2021 (May 17, 2021): 1–10. http://dx.doi.org/10.1155/2021/5534848.

Full text

Abstract:

In recent years, the conjugation of superparamagnetic iron oxide nanoparticles (SPIONs), as tumor-imaging probes for magnetic resonance imaging (MRI), with tumor targeting peptides possesses promising advantages for specific delivery of MRI agents. The objective of the current study was to design a targeted contrast agent for MRI based on Fe3O4 nanoparticles conjugated triptorelin (SPION@triptorelin), which has a great affinity to the GnRH receptors. The SPIONs-coated carboxymethyl dextran (SPION@CMD) conjugated triptorelin (SPION@CMD@triptorelin) were synthesized using coprecipitation method and characterized by DLS, TEM, XRD, FTIR, Zeta, and VSM techniques. The relaxivities of synthetized formulations were then calculated using a 1.5 Tesla clinical magnetic field. MRI, quantitative cellular uptake, and cytotoxicity level of them were estimated. The characterization results confirmed that the formation of SPION@CMD@triptorelin has been conjugated with a suitable size. Our results demonstrated the lack of cellular cytotoxicity of SPION@CMD@triptorelin, and it could increase the cellular uptake of SPIONs to MDA-MB-231 cancer cells 6.50-fold greater than to SPION@CMD at the concentration of 75 μM. The relaxivity calculations for SPION@CMD@triptorelin showed a suitable r2 and r2/r1 with values of 31.75 mM−1·s−1 and 10.26, respectively. Our findings confirm that triptorelin-targeted SPIONs could provide a T2-weighted probe contrast agent that has the great potential for the diagnosis of GnRH-positive cancer in MRI.

APA, Harvard, Vancouver, ISO, and other styles

35

Bahl, Amit, Amarnath Challapalli, Susan Masson, Serena Hilman, Katrina Hurley, and Rajendra Persad. "A randomized controlled trial to determine the effect of triptorelin on reduction of prostate volume preradiotherapy compared with standard therapy (goserelin)." Journal of Clinical Oncology 34, no. 2_suppl (January 10, 2016): 30. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.30.

Full text

Abstract:

30 Background: Hormone therapy in combination with radiotherapy is a curative treatment option for prostate cancer (CaP). Neoadjuvant goserelin is known to reduce prostate gland volume by about 26%, such that radiotherapy treatment volumes are smaller, reducing the risk of damage to bladder and rectum. Triptorelin is 100 times more potent than native LHRH and has a longer half life than both native LHRH and goserelin. This study evaluated the equivalence of cytoreductive efficacy of neoadjuvant triptorelin and goserelin. Methods: Seventy-onepatients with localized CaP who have chosen radical radiotherapy had been randomized by stratified block design, toreceive either triptorelin (n=37) or goserelin (n=34) with bicalutamide cover. Prostate volume was measured at baseline and 14 weeks after start of therapy on transrectal ultrasound (TRUS). PSA, testosterone levels, and EQ5D, QLQ-PR25, QLQ-C30 questionnaires were completed at baseline, 6, 10, and 14 weeks after start of therapy. All the patients had subsequent radical radiotherapy and followed up as per departmental protocol. Changes in TRUS volume and time to castrate levels of testosterone were evaluated. Results: The mean (±S.D) baseline prostate volume in the goserelin and triptorelin groups was 38.1(±12.8) cc and 39.4(±17.5) cc, respectively. The mean (±S.D) reduction in the prostate volume after 14 weeks of goserelin and triptorelin was 36.8(±18.4)% and 32.5(±20.9)%, respectively (p=0.36: Analysis of Covariance). Twenty-nine out of 34 in the goserelin group and 33 out of 37 patients in the triptorelin group achieved castrate levels of testosterone (£0.5nmol/L). The median time to castration was 6.1 (95% CI: 5.8-6.5) and 6.4 (95% CI: 5.9-10.0) weeks for goserelin and triptorelin, respectively (p=0.72: log rank). Conclusions: Goserelin and triptorelin both caused a reduction inprostate volume and achieved castrate levels of testosterone. The cytoreductive efficacy of neoadjuvant triptorelin was equivalent (non-inferior) to that of goserelin. To our knowledge, this is the first reported prospective randomized data demonstrating the equivalence of goserelin and triptorelin in the neoadjuvant setting. Clinical trial information: 2008-007028-25.

APA, Harvard, Vancouver, ISO, and other styles

36

Tkalia, I. G., L. I. Vorobyova, A. N. Grabovoy, V. S. Svintsitsky, and T. O. Tarasova. "THE ANTITUMOR EFFICACY OF CISPLATIN IN COMBINATION WITH TRIPTORELIN AND EXEMESTANE THERAPY FOR AN OVARIAN CANCER ASCITES MODEL IN WISTAR RATS." Experimental Oncology 37, no. 1 (March 22, 2015): 30–35. http://dx.doi.org/10.31768/2312-8852.2015.37(1):30-35.

Full text

Abstract:

Aim: To study antitumor activity of triptorelin — agonist of gonadotropin-releasing hormone and exemestane — inhibitor of aromatase in combination with cisplatin on the model of receptor-positive for estrogens and progesterone malignant transplantable ascites ova rian tumor (OT); to assess tumor response to treatment and VEGF expression in tumor cells under different combinations of cytostatic and hormonal drugs. Materials and Methods: 36 female Wistar rats, which underwent intraperitoneal transplantation of ascites OT (5×106 cells per animal), have been involved in the study. Rats were distributed into 4 groups (9 rats in each group): group 1 — animals, which received combination of cisplatin and triptorelin; group 2 — rats treated with combination of cisplatin and exemestane; group 3 — animals, which were administered with combination of cisplatin, triptorelin and exemestane; group 4 — rats, which received combination of triptorelin and exemestane. Histological study with assessment of treatment pathomorphosis in OT and immunohistochemical study have been carried out to analyze VEGF expression in OT cells. Survival of animals has been evaluated. Results: Combination of cytostatic agent with triptorelin or exemestane has demonstrated significantly higher rates of treatment pathomorphosis (10.1 ± 0.1% and 16.2 ± 0.3%, respectively) and antiangiogenic activity in OT (21.4 ± 1.4% and 15.0 ± 1.3%, respectively), as well as the highest survival of animals (100.0 and 85.7%, respectively) as compared with the same in rats treated in regimen of monotherapy with cisplatin, triptorelin, exemestane or by combination of hormonal drugs. Among animals treated by combination of cytostatic drug with triptorelin, two were cured (22.2%), and among rats, which received cisplatin and exemestane, one animal (11.1%) was cured. Conclusions: Triptorelin and exemestane increase antitumor activity of cisplatin in respect to the transplantable malignant ascites OT and significantly increase survival of animals, especially when triptorelin and cisplatin are used in combination.

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Flutamide/triptorelin." Reactions Weekly &NA;, no. 1320 (September 2010): 25. http://dx.doi.org/10.2165/00128415-201013200-00083.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

&NA;. "Menotropins/triptorelin." Reactions Weekly &NA;, no. 1089 (February 2006): 19–20. http://dx.doi.org/10.2165/00128415-200610890-00061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

&NA;. "Leuprorelin/triptorelin." Reactions Weekly &NA;, no. 538 (February 1995): 10. http://dx.doi.org/10.2165/00128415-199505380-00037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

&NA;. "Goserelin/triptorelin." Reactions Weekly &NA;, no. 493 (March 1994): 8. http://dx.doi.org/10.2165/00128415-199404930-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

&NA;. "Cyproterone/triptorelin." Reactions Weekly &NA;, no. 526 (November 1994): 5. http://dx.doi.org/10.2165/00128415-199405260-00013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

&NA;. "Letrozole/triptorelin." Reactions Weekly &NA;, no. 1298 (April 2010): 21. http://dx.doi.org/10.2165/00128415-201012980-00062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

&NA;. "Letrozole/triptorelin." Reactions Weekly &NA;, no. 979 (November 2003): 14–15. http://dx.doi.org/10.2165/00128415-200309790-00046.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Lai, Cecilia, Dominic A. Solimando, and J. Aubrey Waddell. "Gemtuzumab Triptorelin." Hospital Pharmacy 36, no. 2 (February 2001): 144–49. http://dx.doi.org/10.1177/001857870103600202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Lebret, Thierry, Jerome Rigaud, Gilles Crehange, Nathalie Pello Leprince Ringuet, Anne-Sophie Grandoulier, and Antoine Thiery-Vuillemin. "Treatment of aggressive prostate cancers in real life: Initiation, schedule, and management of triptorelin treatment (TALISMAN)—Design of the study." Journal of Clinical Oncology 39, no. 6_suppl (February 20, 2021): TPS173. http://dx.doi.org/10.1200/jco.2021.39.6_suppl.tps173.

Full text

Abstract:

TPS173 Background: Prostate cancer (PCa) treatment management mostly depends on tumor aggressiveness and patient frailty. Guidelines recommend an intensification of treatment in high risk PCa, with a longer duration of androgen deprivation therapy (ADT), and, for more advanced cases, an administration for life, on top of which additional treatments may be proposed. This implies a holistic management of the patient, including management of comorbidities and ADT side effects. Triptorelin is a widely used gonadotropin-releasing hormone agonist (GnRHa). Generating data on the use of triptorelin in real life will help physicians to analyze the parameters influencing the choice of the planned duration of treatment. Methods: This prospective, multicenter, non-interventional study is conducted in France. Patients are recruited by urologists, radiation oncologists and medical oncologists. Main inclusion criteria are a histologically confirmed PCa, eligible for triptorelin therapy in its label, with a planned total duration of triptorelin treatment of at least 12 months. Decision of triptorelin treatment is made before the inclusion in the study, in the routine practice. 3 visits are planned: V1 (baseline), V2 (at 6 months), V3 (at 12 months). Primary objective of the study is to describe the proportion of patients treated continuously with triptorelin during 12 months following treatment initiation. 786 patients are planned to be enrolled, this will allow to estimate the proportion of patients treated continuously with triptorelin during 12 months following treatment initiation for an expected proportion of 80% with a precision of 3 % taking into account a drop out rate of 15%. Main secondary objectives are to describe the planned total duration of triptorelin treatment and main reason of choice, to identify parameters (tumor aggressiveness criteria, patient frailty...) associated with this planned duration, to describe the formulation and route of administration of triptorelin and reasons of choice, to identify parameters associated with this choice, to describe the change from baseline in quality of life evaluated through QLQ-PR25 questionnaire, and to describe the safety of triptorelin in the real world setting. An interim analysis on baseline data will be performed once 50% of patients are enrolled. It will focus on planned total duration of triptorelin at initiation, main reasons of choice according to circumstances of prescription, formulation and route of administration, and their reasons of choice. Clinical trial information: NCT04593420.

APA, Harvard, Vancouver, ISO, and other styles

46

&NA;. "Cyproterone/triptorelin/buserelin." Reactions Weekly &NA;, no. 299 (May 1990): 6. http://dx.doi.org/10.2165/00128415-199002990-00021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Clomifene/menotropins/triptorelin." Reactions Weekly &NA;, no. 735 (January 1999): 7. http://dx.doi.org/10.2165/00128415-199907350-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

&NA;. "Gonadotropins/progesterone/triptorelin." Reactions Weekly &NA;, no. 1359 (July 2011): 19. http://dx.doi.org/10.2165/00128415-201113590-00070.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

&NA;. "Letrozole/leuprorelin/triptorelin." Reactions Weekly &NA;, no. 1412 (July 2012): 29. http://dx.doi.org/10.2165/00128415-201214120-00108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Ethisterone/ganirelix/triptorelin." Reactions Weekly &NA;, no. 1421 (September 2012): 24. http://dx.doi.org/10.2165/00128415-201214210-00081.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!